PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Ospemifene - Vaginal atrophy
PAD Profile : Ospemifene - Vaginal atrophy
Keywords :
menopause, vaginal oestrogen, oestrogen deficiency, vaginal dryness
Brand Names Include :
Senshio
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 May 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey & North West Sussex Area Prescribing Committee updated their recommendations in line with NICE guidance NG23 Menopause diagnosis and management in May 2020.
Ospemifene is not recommended for menopausal symptoms and a NON FORMULARY traffic light status has been agreed. Please refer to the Menopause -NG23 briefing paper attached below for further information (Page 16). Ospemifene is not a cost effective treatment option for urogenital atrophy. See oestrogen preparations [insert link to oestrogen PAD page)
Associated BNF Codes
06. Endocrine System
06.04.01. Female sex hormones and their modulators
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.02.01. Preparations for vaginal and vulval changes